Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
28 pending office actions • 16 art units • 26 examiners • 0 of 28 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days
The Children's Hospital of Philadelphia maintains a robust portfolio with 27 pending office actions in the Biotechnology & Pharmaceuticals technology area. The prosecution is highly decentralized, involving 25 distinct examiners across 16 distinct art units. This diversity of examiners suggests that the hospital's intellectual property covers a wide range of specific sub-disciplines within the broader biotech sector. The count of 16 distinct art units indicates that the portfolio requires coordination across many different USPTO divisions.
MYERS, CARLA J is the busiest examiner for the portfolio, yet they are responsible for only 2 pending office actions. This low concentration of work with any single examiner, compared to the 27 total actions, implies that the applicant must manage a high volume of unique examiner preferences and art unit trends. With the number of distinct examiners nearly matching the total actions, the hospital's legal team must adapt to a wide variety of examination styles rather than relying on established relationships with a few key individuals.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (7%) |
| §103 only | 7 (25%) |
| §102 only | 1 (4%) |
| §112 only | 4 (14%) |
| Double-patenting + other | 3 (11%) |
| Multi-statute (no §101) | 11 (39%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MYERS, CARLA J | 2 | 49.3% | +46.1% |
| MCLEOD, AFRICA MHAIRIE | 2 | 51.9% | +67.5% |
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
| OLSON, ANDREA STEFFEL | 1 | 62.3% | -11.9% |
| PHAM, KHAI QUYNH TIEN | 1 | 0.0% | +0.0% |
| HAMMOND, ELLEN CHRISTINA | 1 | 78.2% | +11.4% |
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
| MATTHEWS, CHRISTINE HOPKINS | 1 | 71.7% | +31.3% |
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18820706 | FASORACETAM CRYSTALLINE FORMS | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17916998 | DECELLULARIZED MENISCAL CARTILAGE AND USES THEROF | MITCHELL, EDWIN COLEMAN | 111d overdue |
| 18033627 | COMPOSITIONS AND METHODS FOR IN VIVO GENE TRANSFER | SHIN, DANA H | 37d overdue |
| 18713342 | FLAVANOID CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | OLSON, ANDREA STEFFEL | — |
| 18703128 | TARGET ENRICHMENT AND QUANTIFICATION UTILIZING ISOTHERMALLY LINEAR-AMPLIFIED PROBES | PHAM, KHAI QUYNH TIEN | — |
| 18294733 | POSTERIOR LATERAL OFFSET BASED SPINAL CORRECTION SYSTEM | HAMMOND, ELLEN CHRISTINA | — |
| 18497386 | METHODS OF DIAGNOSING AND TREATING CONDUCT DISORDER | KOSAR, ANDREW D | — |
| 18557664 | TRANSFER TRAY AND PRIMING CART FOR NEONATAL CANNULATION AND RELATED METHODS | MATTHEWS, CHRISTINE HOPKINS | — |
| 18557033 | ADENO-ASSOCIATED VIRAL VECTORS FOR TRANSDUCTION OF COCHLEA | MATALKAH, FATIMAH KHALAF | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17265302 | ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION AND THERAPEUTIC METHODS | MCLEOD, AFRICA MHAIRIE | 8d overdue |
| 18294733 | POSTERIOR LATERAL OFFSET BASED SPINAL CORRECTION SYSTEM | HAMMOND, ELLEN CHRISTINA | — |
| 18497386 | METHODS OF DIAGNOSING AND TREATING CONDUCT DISORDER | KOSAR, ANDREW D | — |
| 18557664 | TRANSFER TRAY AND PRIMING CART FOR NEONATAL CANNULATION AND RELATED METHODS | MATTHEWS, CHRISTINE HOPKINS | — |
| 18557033 | ADENO-ASSOCIATED VIRAL VECTORS FOR TRANSDUCTION OF COCHLEA | MATALKAH, FATIMAH KHALAF | — |
| 18287150 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF H-ABC LEUKODYSTROPHY | HUDSON, AMY ROSE | — |
| 18044471 | GENETIC ALTERATIONS ASSOCIATED WITH EOSINOPHILIC ESOPHAGITIS AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF DISEASE | MYERS, CARLA J | — |
| 18006975 | IN UTERO AND POSTNATAL GENE EDITING AND THERAPY FOR TREATMENT OF MONOGENIC DISEASES, INCLUDING MUCOPOLYSACCHARIDOSIS TYPE 1H AND OTHER DISORDERS | MCLEOD, AFRICA MHAIRIE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 4 |
| 1682 | 3 |
| 1636 | 2 |
| 1656 | 2 |
| 1634 | 2 |
| 3773 | 1 |
| 1625 | 1 |
| 1638 | 1 |
| 1615 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18820706 | FASORACETAM CRYSTALLINE FORMS | AULAKH, CHARANJIT | — | §102§103§112DP | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18713342 | FLAVANOID CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | OLSON, ANDREA STEFFEL | — | §101§102§103§112DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18703128 | TARGET ENRICHMENT AND QUANTIFICATION UTILIZING ISOTHERMALLY LINEAR-AMPLIFIED PROBES | PHAM, KHAI QUYNH TIEN | — | §102§103§112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18294733 | POSTERIOR LATERAL OFFSET BASED SPINAL CORRECTION SYSTEM | HAMMOND, ELLEN CHRISTINA | 3773 | §102§103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18497386 | METHODS OF DIAGNOSING AND TREATING CONDUCT DISORDER | KOSAR, ANDREW D | 1625 | §103§112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18557664 | TRANSFER TRAY AND PRIMING CART FOR NEONATAL CANNULATION AND RELATED METHODS | MATTHEWS, CHRISTINE HOPKINS | — | §102§103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18557033 | ADENO-ASSOCIATED VIRAL VECTORS FOR TRANSDUCTION OF COCHLEA | MATALKAH, FATIMAH KHALAF | 1638 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18287150 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF H-ABC LEUKODYSTROPHY | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Oct 16, 2023 |
| 18553893 | ANTIMICROBIAL ELUTING AIRWAY DEVICES | CRAIGO, WILLIAM A | 1615 | §103 | Final Rejection | — | Pending | Oct 04, 2023 |
| 18282653 | ENEMA ASSIST DEVICE | VOKES, KATHLEEN PAIGE | 3783 | §102§103 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18033627 | COMPOSITIONS AND METHODS FOR IN VIVO GENE TRANSFER | SHIN, DANA H | 1635 | §102§112 | Final Rejection | 37d overdue | Pending | Apr 25, 2023 |
| 18044471 | GENETIC ALTERATIONS ASSOCIATED WITH EOSINOPHILIC ESOPHAGITIS AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF DISEASE | MYERS, CARLA J | 1682 | §112 | Non-Final OA | — | Pending | Mar 08, 2023 |
| 18176546 | Compositions and Methods for Modulating Factor IX Function | TSAY, MARSHA M | 1656 | §103 | Non-Final OA | 73d overdue | Pending | Mar 01, 2023 |
| 18007407 | NOVEL THERAPEUTIC USES OF COMPOUNDS FOR ENHANCING MITOCHONDRIAL FUNCTION AND TREATING MITOCHONDRIAL DISEASES | CHO, DAVID H | 1693 | §103Other | Final Rejection | 12d | Pending | Jan 30, 2023 |
| 18006975 | IN UTERO AND POSTNATAL GENE EDITING AND THERAPY FOR TREATMENT OF MONOGENIC DISEASES, INCLUDING MUCOPOLYSACCHARIDOSIS TYPE 1H AND OTHER DISORDERS | MCLEOD, AFRICA MHAIRIE | 1635 | §102§103§112 | Non-Final OA | — | Pending | Jan 26, 2023 |
| 17938857 | Compositions and Methods for Treating Huntington's Disease and Related Disorders | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102 | Final Rejection | 40d | Pending | Oct 07, 2022 |
| 17916998 | DECELLULARIZED MENISCAL CARTILAGE AND USES THEROF | MITCHELL, EDWIN COLEMAN | 1619 | §103§112 | Final Rejection | 111d overdue | Pending | Oct 04, 2022 |
| 17787433 | NOVEL DRUGGABLE TARGETS FOR THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND METHODS FOR DIAGNOSIS AND TREATMENT USING THE SAME | KAPUSHOC, STEPHEN THOMAS | 1683 | §112 | Non-Final OA | 56d | Pending | Jun 20, 2022 |
| 17777245 | COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION | MCKNIGHT, CIARA A | 1656 | §103DP | Non-Final OA | — | Pending | May 16, 2022 |
| 17694841 | Viral Vectors for Prophylaxis and Therapy of Hemoglobinopathies | MARVICH, MARIA | 1634 | §112 | Non-Final OA | — | Pending | Mar 15, 2022 |
| 17641502 | COMPOSITIONS COMPRISING RARE GENETIC SEQUENCE VARIANTS ASSOCIATED WITH PULMONARY FUNCTION AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF ASTHMA IN AFRICAN AMERICAN PATIENTS | MYERS, CARLA J | 1682 | §112 | Non-Final OA | — | Pending | Mar 09, 2022 |
| 17641650 | NOVEL GENETIC MARKERS FOR POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS) AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF THE SAME | SWITZER, JULIET CAROLINE | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 09, 2022 |
| 17289877 | T CELLS FROM LYMPHATIC FLUID FOR DIAGNOSTIC AND THERAPEUTIC USE | REDDIG, PETER J | 1646 | §103 | Non-Final OA | 30d overdue | Pending | Apr 29, 2021 |
| 17279542 | 2' FANA MODIFIED FOXP3 ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112 | Non-Final OA | — | Pending | Mar 24, 2021 |
| 17272005 | SCALABLE TAGGING OF ENDOGENOUS GENES BY HOMOLOGY-INDEPENDENT INTRON TARGETING | REGA, KYLE THOMAS | 1636 | §103 | Final Rejection | 16d | Pending | Feb 26, 2021 |
| 17265302 | ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION AND THERAPEUTIC METHODS | MCLEOD, AFRICA MHAIRIE | 1635 | §103DP | Non-Final OA | 8d overdue | Pending | Feb 02, 2021 |
| 17055075 | CRISPR INTERFERENCE BASED HTT ALLELIC SUPPRESSION AND TREATMENT OF HUNTINGTON DISEASE | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | 31d overdue | Pending | Nov 12, 2020 |
| 16344298 | GENE TRANSFER COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEGENERATIVE DISEASES | FONTAINHAS, AURORA M | 1675 | §103Other | Final Rejection | — | Pending | Apr 23, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial